NasdaqCM - Delayed Quote USD

Mereo BioPharma Group plc (MREO)

3.1700 +0.2100 (+7.09%)
At close: May 15 at 4:00 PM EDT
3.1500 -0.02 (-0.63%)
After hours: May 15 at 7:56 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
10,000.0000
10,000.0000
--
49,213.1617
--
Cost of Revenue
2,574.0000
2,574.0000
-1,146.0000
24,169.2985
--
Gross Profit
7,426.0000
7,426.0000
1,146.0000
25,043.8632
--
Operating Expense
34,562.0000
34,562.0000
53,844.0000
53,299.8623
51,199.9673
Operating Income
-27,136.0000
-27,136.0000
-52,698.0000
-28,255.9991
-51,199.9673
Net Non Operating Interest Income Expense
-750.0000
-750.0000
-3,335.0000
-5,426.8902
-8,638.9468
Other Income Expense
-2,112.0000
-2,112.0000
13,095.0000
52,903.0691
-167,003.2844
Pretax Income
-29,998.0000
-29,998.0000
-42,938.0000
19,220.1798
-226,842.1985
Tax Provision
-532.0000
-532.0000
-718.0000
2,046.0496
-3,845.8918
Net Income Common Stockholders
-29,466.0000
-29,466.0000
-42,220.0000
17,174.1302
-222,996.3067
Average Dilution Earnings
--
--
--
-51,992.0641
--
Diluted NI Available to Com Stockholders
-29,466.0000
-29,466.0000
-42,220.0000
-34,817.9340
-222,996.3067
Basic EPS
-0.20
--
-0.36
0.13
-3.27
Diluted EPS
-0.20
--
-0.36
-0.34
-3.27
Basic Average Shares
131,890.7840
--
113,986.6670
105,563.7300
67,790.6280
Diluted Average Shares
131,890.7840
--
113,986.6670
111,055.1620
67,790.6280
Total Operating Income as Reported
-28,416.0000
-28,416.0000
-54,426.0000
-28,255.9991
-51,199.9673
Total Expenses
37,136.0000
37,136.0000
52,698.0000
77,469.1608
51,199.9673
Net Income from Continuing & Discontinued Operation
-29,466.0000
-29,466.0000
-42,220.0000
17,174.1302
-222,996.3067
Normalized Income
-27,401.2780
-27,401.2780
-54,028.1881
-30,097.2380
-58,824.4027
Interest Income
2,131.0000
2,131.0000
840.0000
1.3496
6.8141
Interest Expense
2,881.0000
2,881.0000
4,175.0000
5,399.8974
8,698.9111
Net Interest Income
-750.0000
-750.0000
-3,335.0000
-5,426.8902
-8,638.9468
EBIT
-27,117.0000
-27,117.0000
-38,763.0000
24,620.0772
-218,143.2874
EBITDA
-26,056.0000
-26,056.0000
-37,874.0000
25,486.5441
-215,964.1304
Reconciled Cost of Revenue
2,574.0000
2,574.0000
-1,146.0000
24,169.2985
--
Reconciled Depreciation
1,061.0000
1,061.0000
889.0000
866.4669
2,179.1570
Net Income from Continuing Operation Net Minority Interest
-29,466.0000
-29,466.0000
-42,220.0000
17,174.1302
-222,996.3067
Total Unusual Items Excluding Goodwill
-2,102.0000
-2,102.0000
12,009.0000
52,903.0691
-167,003.2844
Total Unusual Items
-2,102.0000
-2,102.0000
12,009.0000
52,903.0691
-167,003.2844
Normalized EBITDA
-23,954.0000
-23,954.0000
-49,883.0000
-27,416.5250
-48,960.8460
Tax Rate for Calcs
0.0000
0.0000
0.0000
0.0001
0.0000
Tax Effect of Unusual Items
-37.2780
-37.2780
200.8119
5,631.7009
-2,831.3804
12/31/2020 - 4/24/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PDSB PDS Biotechnology Corporation
3.5000
-0.99%
 
XFOR X4 Pharmaceuticals, Inc.
0.9762
-0.93%
 
DAWN Day One Biopharmaceuticals, Inc.
16.42
-1.20%
 
MDNAF Medicenna Therapeutics Corp.
1.8150
-4.47%
 
EFTR eFFECTOR Therapeutics, Inc.
1.9800
-1.00%
 
CLRB Cellectar Biosciences, Inc.
3.3600
+5.66%
 
CRVS Corvus Pharmaceuticals, Inc.
2.2200
-1.77%
 
LPTX Leap Therapeutics, Inc.
2.8000
+1.82%
 
RARE Ultragenyx Pharmaceutical Inc.
41.12
+0.37%
 
CYTK Cytokinetics, Incorporated
60.50
+1.92%